Year: 2025
Type: article
Abstract: Evaporative Dry Eye Disease (DED), primarily driven by Meibomian Gland Dysfunction (MGD), affects over 30 million individuals in the United States.Tixel i ® , a recently FDA-cleared, non-invasive device, applies localized heat and pressure to the external eyelid surface using Thermo-Mechanical Action ® (TMA ® ).This commentary reviews findings pivotal studies, regulatory submissions, and real-world clinical experience demonstrating Tixel i's safety, tolerability, and sustained improvements in TBUT, MGS, and OSDI.Real-world results in both routine and treatment-resistant patients further support its versatility.With a short treatment duration, minimal discomfort, and durable clinical outcomes, Tixel i offers an efficient, first-line option for managing DED associated with MGD.
Source: JOJ Ophthalmology
Authors: Noaman Sanni, Debra Koloms, Brian Case, Lauren Bailey
Language: English
Field: Medicine
Domain: Health Sciences
Open Access status: diamond
OpenAlex ID: W4410136780